Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorglumide
- Development stage
- Preclinical
- Lead developer
- Meda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lorglumide is a synthetic small-molecule, non-peptide antagonist of the cholecystokinin type A receptor (CCK-A receptor). It inhibits the action of cholecystokinin, a peptide hormone involved mainly in gastrointestinal motility and stimulation of pancreatic enzyme secretion, and has been studied for use in gastrointestinal disorders, pancreatic function, and as a modulator in certain tissue regeneration models. Its mechanism involves competitive antagonism at the CCK-A receptor, preventing endogenous cholecystokinin from binding and exerting its physiological effects[4][8].
- Other names
- lorglumideCR-1409CR1409CR 1409
02
Targets
CCKAR (Cholecystokinin A receptor)
Beyond the preview
Go deeper on lorglumide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorglumide.